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of 136 patients returned their bottles and completed a telephone
survey. At Month 3, 98.53% of patients reported via telephone
that they continually took the drug; 0.74% had temporary inter-
ruptions of the drug; 0.74% discontinued the drug early. At
Month 3, MEMS data for those patients reported 44.85% with
continuous administration, 39.71% with temporary interrup-
tions, 15.44% discontinued early. Kw at Month 3 was 0.036
(95% CI = -0.018, 0.091). At Month 6, 83.82% of patients
reported via telephone that they completed taking the drug;
15.44% were still taking the drug; 0.74% discontinued the drug
early. At Month 6, MEMS data for those patients reported
63.24% completed, 0.74% were still taking, 36.03% discontin-
ued early. Kw at Month 6 was 0.069 (95% CI = -0.005, 0.144).
CONCLUSION: Based on the kappa statistic, there was little
agreement between the patient-reported and electronic methods
of measuring compliance. Patients reported being much more
compliant with their medication regimen than was reported by
MEMS.
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OBJECTIVES: A previous study conducted by the authors indi-
cated that calcium channel blockers, ACE inhibitors, beta block-
ers and diuretics were the four most commonly used therapeutic
classes of antihypertensives in a commercial HMO population.
The objective of this study was to compare adherence between
these four classes of antihypertensives. METHODS: This study
was a retrospective pharmacy claims database analysis. All
members evaluated had a diagnosis of hypertension, received at
least two prescriptions for an antihypertensive drug, and were
continuously enrolled during the one-year study period. The
average medication possession ratio (MPR) was used as a
primary adherence indicator. An analysis of covariance was con-
ducted to determine if differences in the mean MPR existed based
on the antihypertensive therapeutic class. Previous research in
this population indicated that age, units per day of the drug,
number of concurrent medications and total days supply were
signiﬁcant predictors of adherence. These factors were for in this
analysis. RESULTS: The average MPR was evaluated for 1637
members meeting the inclusion criteria. The average age of the
members was 52.85 year and 53.63% were female. The mean
(S.D.) MPR for the therapeutic classes were: ACE inhibitors
0.8626 (0.2370), beta-blockers 0.8534 (0.2288), calcium
channel blockers 0.8770 (0.2078), diuretics 0.8291 (0.2705).
The MPR were signiﬁcantly higher in members on calcium
channel blockers versus diuretics (mean difference = 0.0524,
95% CI = 0.0140–0.0907, p < 0.005) and ACE inhibitors versus
diuretics (mean difference = 0.0473, 95% CI = 0.0139–0.0808,
p < 0.005). There were no signiﬁcant differences in adherence
between the other classes of antihypertensives. CONCLUSIONS:
After controlling for signiﬁcant predictors of adherence, the
MPR for members on calcium channel blockers and ACE
inhibitors were signiﬁcantly higher than for those patients on
diuretics. These results may have implications for the effective-
ness of different therapeutic classes of antihypertensives in blood
pressure control.
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OBJECTIVE: The objective of this study was to quantify the
clinical and economic effects of non-adherence with triple
therapy in treatment-naïve HIV patients. METHODS: A
Markov model was developed to project quality-adjusted life
expectancy and direct medical costs for HIV patients (mean age
= 37 years) on an initial regimen of highly active antiretroviral
therapy (HAART) with efavirenz, lamivudine and extended
release stavudine given once daily. Each month, patients faced a
risk of transition to AIDS that was a function of viral load, CD4
count, and adherence to drug therapy. Patients were assumed to
change to another triple-therapy regimen if their viral load was
≥ 400 copies/mL or if they transitioned to AIDS. After four reg-
imens, patients followed the natural history of the disease. We
compared clinical and economic outcomes for two adherence
scenarios: “clinical trial” (representing ideal utilization observed
in clinical trials) and “typical” (based on observational studies
in actual practice). Costs were derived from the HIV/AIDS Costs
and Services Utilization Survey and average wholesale drug
prices. Future costs and QALYs were discounted 3%. RESULTS:
Mean discounted quality-adjusted life expectancy was 8.6 and
10.0 QALYs under the typical and clinical trial adherence sce-
narios, respectively. Lifetime direct medical costs in the typical
and trial scenarios were $295,000 and $336,000, respectively.
Compared with typical adherence, clinical trial adherence con-
ferred an average gain of 1.4 QALYs at an incremental cost of
$29,000 per QALY gained. Up to $1650 per patient per year
could be spent on an intervention to improve adherence from
typical to trial levels, and the incremental cost-effectiveness of
doing so would remain below $50,000 per QALY gained. CON-
CLUSIONS: Typical adherence with HAART reduces quality-
adjusted life expectancy by 14% compared to adherence levels
in clinical trials. Programs to improve adherence appear to be a
highly cost-effective use of resources.
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OBJECTIVES: Information on the comparative effectiveness of
different antipsychotic medications in a naturalistic setting is
important for clinicians and other health care decision-makers.
However, in long-term naturalistic studies, patients may remain
on treatment, switch, augment, or even stop treatment at any
time and for different reasons—making statements about the
causal effects of treatments difﬁcult. The objective of this
research was to assess several analytic strategies for comparing
treatment effectiveness in the presence of switching. METHODS:
Using data from a recently completed 1-year, randomized, natu-
ralistic, anti-psychotic cost-effectiveness trial for schizophrenia,
three different analysis strategies were utilized to compare the
effectiveness of treatments on schizophrenia symptom severity
(measured by BPRS total score): intent-to-treat, sub-setting by
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treatment patterns, and marginal structural models (MSMs).
MSMs utilize all of the data, account for the treatment switch-
ing, while adjusting for selection bias and patient dropout.
RESULTS: Over 25% of 664 randomized patients switched
treatments during the study, 7% augmented their randomized
treatment, and another 28% discontinued early. Switching was
greatest among patients randomized to conventional anti-
psychotics (45% switched to atypicals, <20% of atypical patients
switched therapies). Treatments did not differ in BPRS total score
using various intent-to-treat analyses including last-observation-
carried-forward. However, MSMs and other approaches that
took into account the treatment switching demonstrated statis-
tically signiﬁcantly greater symptom reduction for patients
treated with olanzapine as compared to conventional anti-
psychotics (overall treatment difference: 4.2 points, p = 0.007).
CONCLUSIONS: Drawing inferences on treatment effects in
longitudinal naturalistic studies is challenging due in part to
patients changing or stopping medications over time. In this
study, standard methods did not address treatment effectiveness,
while MSMs provided a framework for addressing effectiveness
in the presence of switching, selection biases, and early dropout.
The MSM analysis showed olanzapine to be superior to con-
ventional anti-psychotics in reducing schizophrenic symptom
severity.
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OBJECTIVES: The study was conducted to examine following
hypotheses: Tricyclic Antidepressants (TCAs) use increases the
risk of colorectal cancer. In particular, the use of genotoxic TCAs
increases the risk as compared to non-genotoxic TCAs. The use
of Selective Serotonin Reuptake Inhibitors (SSRIs) decreases the
risk of colorectal cancer. METHODS: A population-based nested
case-control study was conducted using source population who
individually participate in the Saskatchewan Prescription Drug
Plan aged 5–82.5 years from 1981–2000 with no previous
history of cancer since 1967. A total of 6544 histologically
proven invasive colorectal cancer patients were identiﬁed from
the Saskatchewan Cancer Registry. For each case, four eligible
non-cancer controls matched on age, gender and calendar time
were randomly selected. The effects of antidepressant use were
examined by conditional logistic regression, considering dosage,
duration and timing of antidepressant use. RESULTS: A signiﬁ-
cant increased risk of colorectal cancer was observed for medium
dose and duration of TCAs use during 16–20 year period pre-
ceding diagnosis without signiﬁcant dose-response effect (Inci-
dence rate ratio (RR) for dose = 1.51, 95% conﬁdence interval
= (1.09–2.09); RR for duration = 1.60 (1.13–2.27)). No signiﬁ-
cant increased risk was observed among users of genotoxic
TCAs, while a signiﬁcantly increased risk was observed among
persons exposed to medium duration of non-genotoxic TCAs
during 16–20 years preceding diagnosis without signiﬁcant dose-
response effect (RR = 1.89 (1.14–3.14)). Signiﬁcant decreased
risk of colorectal cancer was observed among subjects heavily
exposed to SSRIs during 5-year periods preceding diagnosis (RR
for dosage = 0.62 (0.43–0.90), P-value of test for trend = 0.01;
RR for duration = 0.71 (0.50–1.00), P-value of test for trend =
0.008). CONCLUSIONS: No sufﬁcient evidence supporting that
the use of TCAs increases the risk of colorectal cancer. Our
results support the priori hypothesis that the use of SSRIs
decreases the risk of colorectal cancer.
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OBJECTIVE: To deﬁne a method of recognizing inﬂuence 
of comorbid conditions when studying outcomes of a speciﬁc
disease or therapy. Background: Patients are often suffering from
multiple disease states. When looking at resource utilization,
absenteeism, and other outcomes for a speciﬁc disease state or
therapy it is important to recognize the inﬂuence of other dis-
eases to the total costs and outcomes of the disease of interest.
METHODS: Several comorbidity indexes have been developed.
Well known and described are the Charlson Index with adapta-
tions, Index of Coexistent Disease, Cumulative Illness Rating
Scale, Chronic Disease Score and several other disease speciﬁc
indexes. The typical use of these indexes is predictive, a forecast
of mortality or costs based on the current history of a patient.
Many of these indexes require clinical information. The focus of
the current index is strictly toward administrative (claims) data-
bases. RESULTS: The methodology presented here is a nonlin-
ear transformation of the number of comorbid conditions, scaled
so that the probability of signiﬁcant comorbidity increases
monotonically with the number of conditions reported. This
AHRQ Comorbidity Index algorithms described by Elixhauser
are used to deﬁne a set of 31 comorbid conditions as deﬁned by
1111 ICD9 diagnoses. Sensitivity analysis of the number of
expected conditions resulted in a denominator of ten units.
CONCLUSIONS: The denominator to yield a percentage of
costs, outcomes, etc attributable to the comorbid conditions
divides the number of Elixhauser conditions, other than the
disease of interest. This index takes advantage of the longitudi-
nal nature of claims data to be inclusive of all disease states
within a patient and not just the current cause for treatment. It
provides an alternative approach to assign costs, absenteeism,
and other outcomes to a disease state that is a more accurate val-
uation of the outcomes without undue inﬂuence from other
comorbidities.
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OBJECTIVES: Inferring disease descriptions (e.g. asthma, mul-
tiple-sclerosis, etc) in a patient from his/her pharmacy proﬁle is
important in several sectors of health care such as insurance and
medical management. While the inference is relatively straight
forward in a few cases (e.g. diabetes in the presence of insulin),
very often the relationships are multifactorial. Manual, expert-
based processes for the task are unscalable and unmaintainable.
An automated, scalable and accurate method to infer disease
descriptions from a patient’s pharmacy proﬁle is the objective of
this study. METHODS: A large managed care database com-
prised of both medical and pharmacy claims was used for the
implementation. The pharmacy proﬁles were abstracted into
dummy variables based on First Data Bank drug classiﬁcation.
One dummy variable for each disease description based on
medical claims was created, and there were as many dummy vari-
ables as disease descriptions. For the current implementation,
Clinical Care Groups (a product of Ingenix) was chosen as the
disease description standard. To capture the multifactorial nature
of the relationships, logistic regression was used. The process of
creation of several such models was automated. The models were
evaluated based on standard metrics such as concordance rate,
false positives, sensitivity, etc. Performance of the models rela-
